Loading...
NPI 1295147684 · Ocean Springs, MS · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Certus Laboratories, LLC is a clinical medical laboratory provider located in Ocean Springs, Mississippi. This profile covers 17 Medicare and 30 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Certus Laboratories, LLC |
| Address | 3827 Bienville Blvd |
| City | Ocean Springs |
| State | MS |
| ZIP | 39564 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 20, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $2M |
| Medicare | $1.4M |
CERTUS LABORATORIES, LLC operates as a clinical medical laboratory with its billing heavily concentrated in definitive and presumptive drug testing: the provider’s Medicare top three revenue drivers are G0482, G0483 and 80307, and those three codes account for 97.6% of its total Medicare revenue. The code descriptions for G0482 and G0483 indicate high-complexity definitive drug identification by GC/MS or LC/MS methods, while 80307 is a presumptive instrumented drug screen, together signaling a business built around forensic-grade and screening toxicology services.
Revenue concentration is pronounced across both payers: the precomputed top-3 Medicare codes account for 97.6% of Medicare revenue and the top-3 Medicaid codes account for 76.3% of Medicaid revenue. This degree of concentration means the lab’s financial performance is heavily dependent on utilization and reimbursement for a very small set of drug-testing services.
In payer mix terms the provider bills more to Medicaid than to Medicare: reported lifetime revenue is $2M from Medicaid versus $1.4M from Medicare, so Medicaid is the larger revenue stream. That asymmetry suggests state-level contracting and Medicaid payment policies will have outsized influence on overall revenue.
Nationally on Medicare the provider ranks highly on its principal drug-testing codes: G0482 ranks #12 of 1618 providers (99th percentile) and G0483 ranks #45 of 1063 providers (96th percentile), while 80307 ranks #188 of 4760 (96th percentile). Although the dataset labels these volumes as "typical, unremarkable volume for this code," the rank/percentile positions indicate CERTUS is a major national participant for definitive drug testing.
In-state competitive standing on Medicaid is stronger and, for some codes, dominant: G0482 is ranked #1 of 17 providers in-state (100th percentile) and explicitly flagged as an "extreme outlier, far above typical state volume for this code," while G0483 is #2 of 24 (96th percentile) and described as "notably above typical state volume." Those positions imply substantial market share in Mississippi for high-complexity definitive drug testing.
Beyond toxicology, the provider bills a range of nucleic acid amplified tests (e.g., 87798 and multiple pathogen-specific NAATs) but these represent much smaller revenue slices on Medicare and Medicaid compared with the drug-test codes. For Medicaid, 87798 appears as a secondary revenue source ($139.1K, 7.1% of Medicaid revenue), while on Medicare 87798 contributes $8.9K (0.6% of Medicare revenue), indicating a modest but present infectious-disease testing footprint.
The provider’s operational history is established but relatively recent: NPI enumerated 2014-05-20 (~12 years ago). The tenure combined with high-volume definitive drug-testing billing suggests a focused growth strategy in toxicology services over the past decade.
Given the extreme revenue dependence on G0482/G0483 (top-3 shares of 97.6% Medicare and 76.3% Medicaid) and the provider’s dominant in-state ranks for those codes, payers negotiating rates, prior-authorization, or surveillance for drug-testing services should treat CERTUS as a concentrated, high-volume provider where policy or reimbursement changes for those codes would materially affect its revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,980 | $200 | $775.3K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,090 | $240 | $506.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,370 | $60 | $83.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 100 | $110 | $10.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 260 | $30 | $8.9K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 30 | $150 | $4.9K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 90 | $30 | $3.1K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 30 | $30 | $920 |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 30 | $30 | $920 |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 30 | $30 | $880 |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 39 | 50 | 1,050 | $30 | $144.9K |
| G0483 | 3 | 30 | 140 | $240 | $119.3K |
| G0482 | 1 | 20 | 90 | $190 | $92.3K |
| 87481 | 36 | 40 | 540 | $30 | $61.5K |
| 80307 | 3 | 90 | 200 | $60 | $24.1K |
| G0481 | 26 | 40 | 40 | $140 | $16.7K |
| G0480 | 12 | 40 | 50 | $110 | $15.1K |
| 87500 | 23 | 30 | 130 | $30 | $14.5K |
| 87653 | 39 | 40 | 130 | $30 | $13.6K |
| 87640 | 48 | 50 | 90 | $30 | $10.4K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
30 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,890 | $110 | $671.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7,910 | $70 | $577.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 8,220 | $30 | $254.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1,960 | $70 | $139.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,830 | $70 | $122.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1,110 | $40 | $42K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 540 | $50 | $27K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,100 | $10 | $13.2K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 1,100 | $10 | $13.2K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 40 | $350 | $13.1K |
Showing 1–10 of 30
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
30 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 28 | 30 | 240 | $260 | $353.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 15 | 120 | 1,650 | $30 | $115K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 370 | $100 | $114.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 18 | 60 | 560 | $60 | $79.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 179 | 230 | 1,870 | $10 | $70.1K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 55 | 110 | 510 | $20 | $70K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 54 | 110 | 490 | $20 | $68.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 18 | 30 | 310 | $60 | $62.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 20 | 420 | $60 | $61.7K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 100 | 130 | 670 | $20 | $44.8K |
Showing 1–10 of 30
Other providers in the same ZIP code as Certus Laboratories, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Gulf Coast Children's Clinic, PA | MS | Clinic/Center | $0 | $11.2M |
| Mississippi Coast Ob/gyn, P.A. | MS | Obstetrics & Gynecology Physician | $0 | $2M |
| Jason Rector | MS | Pediatric Dentistry | $0 | $1.8M |
| Dva Healthcare Renal Care Inc | MS | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $1.6M |
| Ocean Springs Surgical And Endoscopy Center LLC | MS | Ambulatory Surgical Clinic/Center | $763.4K | $132.9K |
| Michele Hughes | MS | Dermatology Physician | $713.5K | $320 |
| Rishi Roy | MS | Vascular Surgery Physician | $671K | $0 |
| James Sutton | MS | Ophthalmology Physician | $374.1K | $233.4K |
| Edward Aldridge | MS | General Practice Physician | $86.7K | $342.4K |
| Mississippi Eye Surgery Center | MS | Ambulatory Surgical Clinic/Center | $329.4K | $16.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.